Presencia de la mutaci贸n BRAFp>T1799Ap> en el tumor primario como indicador de riesgo, recidiva o persistencia de carcinoma papilar de tiroides

详细信息	查看全文 | 推荐本文 |

• 作者：Marisa Cañ ; adas Garrep>ap>p> ; p>p>marisacgarre@gmail.comp> ; Martí ; n Ló ; pez de la Torre Casaresp>bp> ; Patricia Becerra Massarep>cp> ; Miguel Á ; ngel Ló ; pez Nevotp>dp> ; Jesú ; s Villar Del Moralp>ep> ; Nuria Muñ ; oz P&#233 ; rezp>ep> ; Ricardo Ví ; lchez Joyap>bp> ; Rosa Montes Ramí ; rezp>fp> ; Jos&#233 ; Manuel Llamas Elvirap>ap>
• 关键词：Mutació ; n BRAFT1799A ; Carcinoma papilar de tiroides ; Recidiva tumoral
• 刊名：Endocrinolog铆a y Nutrici贸n
• 出版年：2011
• 期刊代码：pca151_15750922
• 类别：med
• 出版时间：April 2011
• 卷：58
• 期：4
• 页码：175-184
• 文件大小：157 K

摘要

Background and objective

<p>The BRAFp>T1799Ap> mutation is reported to be associated to aggressive, persistent, and recurrent tumor in papillary thyroid carcinoma (PTC) patients. Association of the BRAFp>T1799Ap> mutation in the primary tumor with the clinicopathological characteristics of PTC patients was analyzed.

Patients, material and methods

<p>Ninety-seven PTC patients were followed up for a median of 64.1 months. The BRAFp>T1799Ap> mutation was analyzed in DNA from initial thyroidectomy biopsies by PCR amplification and restriction fragment length polymorphism using TspRI enzyme. Positive cases were confirmed by DNA sequencing. Statistical association between BRAFp>T1799Ap> mutation and clinicopathological characteristics was analyzed by the relevant hypothesis tests and logistic regression.

Results

<p>46.4%of patients were positive for the BRAFp>T1799Ap> mutation. Bivariate and multivariate analysis showed the BRAFp>T1799Ap> mutation to be only associated to age over 60 years (odds ratio [OR] = 5.5; 95%confidence interval [CI],1.4-21.9; p = 0.019) and to tumor size of 1 cm or greater (OR = 3.6, 95%CI, 1.2-10.3; p = 0.016). The BRAFp>T1799Ap> mutation was not associated to histological subtype, metastasis, recurrence, more aggressive treatments (ablative Ip>131p> therapy or surgery), or PTC persistence at the end of follow-up.

Conclusions

<p>The BRAFT1799A mutation is associated to age over 60 and a tumor size of 1 cm or greater, but not to other clinicopathological characteristics, tumor recurrence or PTC persistence.